Molly Robison, | |
4360 Shore Dr Ste 101, Virginia Beach, VA 23455-2994 | |
(186) 693-3838 | |
Not Available |
Full Name | Molly Robison |
---|---|
Gender | Female |
Speciality | Nurse Practitioner - Family |
Location | 4360 Shore Dr Ste 101, Virginia Beach, Virginia |
Accepts Medicare Assignments | Does not participate in Medicare Program. She may not accept medicare assignment. |
Identifier | Type | State | Issuer |
---|---|---|---|
1962921197 | NPI | - | NPPES |
1962321197 | Medicaid | VA | |
1962921197 | Medicaid | VA |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207Q00000X | Family Medicine | 363LF0000X (Virginia) | Secondary |
363LF0000X | Nurse Practitioner - Family | 0024174798 (Virginia) | Primary |
Mailing Address | Practice Location Address |
---|---|
Molly Robison, 4360 Shore Dr Ste 101, Virginia Beach, VA 23455-2994 Ph: (186) 693-3838 | Molly Robison, 4360 Shore Dr Ste 101, Virginia Beach, VA 23455-2994 Ph: (186) 693-3838 |
News Archive
"Super Bowl Sunday is the second highest day for food consumption," says Lisa Cimperman, RD, clinical dietitian at University Hospitals Case Medical Center, "right behind Thanksgiving Day."
NeuroPace, Inc. today announced that it has submitted its Premarket Approval (PMA) application to the U.S. Food and Drug Administration (FDA) for its RNS® System, a novel investigational device that utilizes responsive neurostimulation to monitor and interrupt abnormal electrical activity in the brain before seizures occur. The PMA application is for an indication to treat people with medically refractory partial onset epilepsy originating from one or two locations in the brain.
Digoxin, a drug commonly used to treat heart conditions, was associated with a 71 percent higher risk of death and a 63 percent higher risk of hospitalization among adults with diagnosed atrial fibrillation and no evidence of heart failure, according to a Kaiser Permanente study that appears in the current online issue of Circulation: Arrhythmia and Electrophysiology.
Increasing rates of multidrug-resistant tuberculosis "are hampering world health programs aimed at tackling TB and threaten to wipe out progress made against the disease, scientists said on Friday," Reuters reports (Kelland, 3/18).
› Verified 5 days ago